/* Style Definitions */
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-bidi-font-family:"Times New Roman";
Researchers of the University of Helsinki,Helsinki,Finland,the results of a study published in the June 28 issue of Journal of the American Medical Association show that,after surgical resection of PDE1A gastrointestinal stromal tumors with recurrence of high-risk patients,those receiving Iraq imatinib(a drug to treat certain types of cancer)up to three years rather than years of patients with relapse-free survival and overall survival improvement.According to background information in the article:"gastrointestinal stromal tumors(GIST)usually present in the stomach or small intestine,but it can occur in any part of the gastrointestinal tract,but it is rare in the abdominal cavity in other parts of GIST The malignant potential to aggressive PDE1B cancer ranging from microscopic gastrointestinal stromal tumors after surgery to give 12 months of imatinib treatment improves recurrence-free survival(RFS),recurrence of GIST to stop treatment after the first year is common;suggesting that a period of 12 months of administration may be a short time.Helsinki University Central Hospital,Helsinki,Finland,Heikki Joensuu,MD,and colleagues given to those considered to have recurrence of GIST patients with Pde1c high risk of secondary(post-operative)imatinib treatment for more than three years more than 1 year of treatment results good check.The randomized trial included the removal of KIT(a gene)-positive GIST patients in the surgery,they joined the study in February 2004 to September 2008.200 patients were assigned to a treatment group of 12 months,200 patients were assigned to the treatment group of 36 months;these patients from 24 medical centers in Finland,Germany,Norway and Sweden.Patients randomized to daily oral administration of 400 mg of imatinib imatinib,time or 12 months or 36 months,12 weeks after surgery.
The researchers found that PDE2A medication in the group of 36 patients with relapse-free survival time longer than the medication group of 12 patients with relapse-free survival(5-year RFS was 65.6%vs 47.9%).Group was assigned to take 36 months of imatinib in patients taking the number of deaths during the follow-up period than those people in the group of 12 less the number of PDE3A deaths during follow-up(12 people vs.25 people)longer overall survival time of 36 months the group of patients(5-year survival rates were 92.0%vs 81.7%).The authors also found that patients taking the 36 month group compared with patients taking the 12 month group,the former have a greater proportion of stopped for reasons unrelated to the recurrence of GIST imatinib(51[25.8%]vs 25 people[12.6%];the reasons for its withdrawal adverse reactions,patient preference,tumor histology,is not the GIST and other unknown reasons).Almost all patients who participated in the study at least one documented adverse events;most of the events on the severity was rated as mild.The researchers added that the impact on overall survival is based on a relatively small number of deaths of these patients participated in the study will continue to be tracked to confirm the benefits of overall survival.GIST often stop taking the auxiliary ima relapse after imatinib,it is necessary to carry out longer-treatment evaluation studies,and studies of new agents and combinations thereof.